At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 27, 2026 at 16:21 ET
Agilon health filed a supplement to its proxy statement clarifying the appointment of Tim O'Rourke as CEO, President, and Class III Director. The supplement does not change any proposals or board recommendations for the June 2, 2026 annual meeting. This is a routine disclosure following the previously announced CEO appointment.
- Tim O'Rourke appointed CEO and President, effective May 7, 2026.
- O'Rourke also appointed as Class III Director, term expiring at 2027 annual meeting.
- Compensation includes $850,000 base salary, $500,000 signing bonus, 120,000 RSUs, and 200,000 PSUs with stock price targets ($50, $100, $150).
- Supplement does not alter proposals or board recommendations for the June 2, 2026 annual meeting.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access